1.01
+0.01(+1.00%)
Currency In USD
| Previous Close | 1 |
| Open | 1 |
| Day High | 1.01 |
| Day Low | 0.99 |
| 52-Week High | 1.59 |
| 52-Week Low | 0.77 |
| Volume | 161,780 |
| Average Volume | 662,522 |
| Market Cap | 88.26M |
| PE | -3.37 |
| EPS | -0.3 |
| Moving Average 50 Days | 1.05 |
| Moving Average 200 Days | 1.14 |
| Change | 0.01 |
If you invested $1000 in Cardiol Therapeutics Inc. (CRDL) since IPO date, it would be worth $269.94 as of December 24, 2025 at a share price of $1.01. Whereas If you bought $1000 worth of Cardiol Therapeutics Inc. (CRDL) shares 5 years ago, it would be worth $465.44 as of December 24, 2025 at a share price of $1.01.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Newsfile
Dec 01, 2025 12:27 PM GMT
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evidenc
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Newsfile
Nov 13, 2025 12:45 PM GMT
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceuti
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
Newsfile
Nov 05, 2025 12:45 PM GMT
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a